RYBELSUS 14MG TABLETS
Manufactured By NOVO NORDISK PHARMA INDIA LTD
Composition SEMAGLUTIDE 14MG
RS 3265.32
MRP RS 3628.13
(10% OFF)
Includes all taxes
Package SIZE
( 10`s )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Rybelsus 14mg Tablets
Rybelsus 14mg Tablets (Semaglutide 14mg) is a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk Pharma India Ltd, indicated for the management of type 2 diabetes mellitus (T2DM) in adults as an adjunct to diet and exercise. It is the world's first oral GLP-1 receptor agonist — a groundbreaking advance that provides the proven metabolic benefits of injectable GLP-1 therapy in a convenient tablet form. Available from Shabbir Medical Hall at the best price in India, this genuine prescription medicine is available online with fast delivery.
BENEFITS: Rybelsus 14mg offers a dual clinical advantage for type 2 diabetes management: superior glycaemic control and clinically significant body weight reduction. In the landmark PIONEER clinical trial programme, oral Semaglutide 14mg demonstrated robust HbA1c reductions of up to 1.4% and meaningful weight loss averaging 3–4 kg versus placebo. The once-daily tablet format eliminates injection anxiety, making GLP-1 receptor agonist therapy accessible to a wider patient population including those unwilling or unable to self-inject.
USAGE OVERVIEW: Rybelsus 14mg must be taken on an empty stomach at least 30 minutes before the first food, drink (other than plain water), or other oral medicines of the day. It is swallowed whole with no more than 120ml (half a glass) of plain water. Do not crush, chew, or split the tablet. The dose and treatment regimen are strictly determined by your diabetologist or endocrinologist.
SAFETY OVERVIEW: The most common side effects are gastrointestinal — nausea, vomiting, and diarrhoea — particularly during dose escalation. These are generally transient and manageable. Rare but serious risks include pancreatitis and diabetic retinopathy complications. Rybelsus is NOT indicated for type 1 diabetes or diabetic ketoacidosis. Consult your physician regarding all concurrent medications and conditions before initiating therapy.
Uses / Indications:
• Type 2 Diabetes Mellitus (T2DM): once-daily oral adjunct to diet and exercise to improve glycaemic control in adults
• Monotherapy: when metformin is inappropriate or not tolerated
• Combination therapy: add-on to metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin
• Cardiovascular risk reduction: Semaglutide (injectable) has demonstrated CV benefit; oral form used in high CV-risk T2DM patients
• Weight management support: clinically significant body weight reduction as part of diabetes management
ADDITIONAL USES (off-label / emerging):
• Non-alcoholic fatty liver disease (NAFLD) / NASH — under clinical investigation
• Obesity management in T2DM patients (as part of endocrinologist-directed regimen)
• Pre-diabetes with high cardiovascular risk — specialist-guided use
Interactions / Warnings:
CONTRAINDICATIONS: Type 1 Diabetes Mellitus — Rybelsus is NOT indicated; risk of diabetic ketoacidosis. Diabetic Ketoacidosis (DKA) — do not use in active DKA. Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 RAs have shown thyroid C-cell tumours in animal studies (relevance to humans unclear but precaution advised). Multiple Endocrine Neoplasia type 2 (MEN 2) — contraindicated. Severe gastrointestinal disease (gastroparesis, inflammatory bowel disease) — use with caution; GI side effects may be poorly tolerated.
PANCREATITIS WARNING: Cases of acute pancreatitis have been reported with GLP-1 receptor agonists. Discontinue immediately if pancreatitis is suspected. Do NOT restart Rybelsus after confirmed pancreatitis.
DIABETIC RETINOPATHY: Rapid glycaemic improvement with Semaglutide has been associated with transient worsening of diabetic retinopathy. Ophthalmological assessment recommended at baseline and during treatment in patients with pre-existing retinopathy.
RENAL FUNCTION: GI-induced dehydration (vomiting/diarrhoea) can precipitate acute kidney injury — ensure adequate hydration and seek medical review if persistent.
THYROID: Report any neck masses, difficulty swallowing, hoarseness, or persistent neck pain to your physician immediately.
DRIVING & MACHINERY: Dizziness may occur, especially early in treatment or if hypoglycaemia develops with combination therapy. Assess personal response before driving.
ELDERLY USE (>=65 years): No age-specific dose adjustment required; however, elderly patients may be more susceptible to dehydration from GI side effects — monitor carefully.
PAEDIATRIC USE: Rybelsus is NOT approved for use in patients under 18 years of age.
Pregnancy interaction:
• Rybelsus 14mg (Semaglutide) is CONTRAINDICATED in pregnancy
• Animal studies have shown reproductive toxicity including embryotoxicity and teratogenicity at clinically relevant exposures
• Human data are limited; however, given the mechanism and animal data, Rybelsus should NOT be used during pregnancy
• Women planning pregnancy should stop Rybelsus at least 2 months before attempting conception (due to the long half-life of the drug class)
• If pregnancy is detected during treatment, discontinue Rybelsus immediately and consult your endocrinologist for alternative diabetes management (typically insulin)
• Effective contraception is recommended for all women of childbearing potential during Rybelsus treatment
BREASTFEEDING:
• It is unknown whether Semaglutide is excreted into human breast milk
• Due to the potential for serious adverse effects in nursing infants, breastfeeding is NOT recommended during Rybelsus treatment
• Discuss alternative diabetes management options with your physician if breastfeeding
DOCTOR CONSULTATION WARNING:
• Never stop Rybelsus without consulting your diabetologist. Abrupt discontinuation can cause loss of glycaemic control and HbA1c rebound
Expert advice:
1. THE 30-MINUTE RULE IS NON-NEGOTIABLE:
• The most critical factor for Rybelsus efficacy is the absorption window. Rybelsus must be taken on a completely empty stomach with up to 120ml of plain water ONLY — at least 30 minutes before any food, other drink, or other oral medication. Even a sip of coffee or juice before the 30-minute mark significantly reduces semaglutide absorption (by up to 50% in some studies). Set a daily phone alarm to build this habit.
2. NEVER CRUSH, CHEW, OR SPLIT THE TABLET:
• The SNAC absorption-enhancing coating must remain intact for adequate gastric mucosal absorption. Crushing or splitting destroys this mechanism entirely.
3. MANDATORY DOSE ESCALATION — DO NOT SKIP STEPS:
• Starting directly at 14mg causes severe, treatment-limiting nausea and vomiting. The escalation protocol (3mg for 30 days → 7mg for 30 days → 14mg) is clinically designed to build GI tolerability. If you missed a dose-escalation step, contact your diabetologist before increasing dose.
4. HYPOGLYCAEMIA RISK WITH COMBINATION THERAPY:
• Rybelsus alone has a very low risk of hypoglycaemia. However, when combined with sulfonylureas or insulin, the risk increases significantly. Always carry glucose tablets or a fast-acting sugar source. Know the signs of hypoglycaemia: sweating, tremor, confusion, palpitations, hunger.
5. MONITOR FOR PANCREATITIS SYMPTOMS:
• If you experience severe, persistent abdominal pain — especially if it radiates to your back — STOP taking Rybelsus and seek immediate medical attention. Do NOT wait to see if it resolves.
MONITORING ADVICE:
• HbA1c: every 3 months for the first year; every 6 months once stable at target
• Fasting blood glucose and post-meal glucose: self-monitoring as directed by your diabetologist
• Renal function (eGFR, creatinine): at baseline and annually (or more frequently if GI side effects are severe)
• Body weight: monthly — expected weight reduction is a therapeutic benefit
• Diabetic retinopathy: baseline ophthalmic assessment; annual review or sooner if visual symptoms develop
• Lipid profile & blood pressure: periodically — Semaglutide has favourable effects on both
• Liver function: if signs of hepatic disease develop
COMPLIANCE TIPS:
• Store at room temperature (below 30°C) in original blister pack — NOT in the fridge
• Take at the same time each morning — consistency in timing maximises absorption and glucose control
• If you miss a dose: skip that day entirely — do NOT take Rybelsus later in the day (food already consumed)
• Use a diabetes management app (e.g., mySugr, Rybelsus MyDiabetesHome) to log glucose readings and doses
• Carry your prescription and a diabetes medical alert card at all times
• Do not share your medication — Rybelsus is prescribed based on individual patient assessment
SAFETY TIPS:
• Eat small, low-fat meals to minimise nausea during the first 4–8 weeks of escalation
• If nausea is severe: take Rybelsus in the evening on an empty stomach (if no other medications conflict) — discuss with diabetologist
• Stay well hydrated — dehydration from GI side effects can strain kidneys; drink water throughout the day
• Avoid alcohol excess — worsens GI side effects and increases hypoglycaemia risk with combination therapy
• Inform your dentist, surgeon, and any other treating physician that you are taking Rybelsus — gastric emptying delay affects anaesthesia planning
Side Effects:
• Nausea (most common, especially during dose escalation; typically resolves within 4–8 weeks)
• Vomiting
• Diarrhoea
• Abdominal pain, discomfort, or bloating
• Decreased appetite (pharmacological effect; generally desired in overweight T2DM patients)
• Constipation
• Dyspepsia / acid reflux / belching
LESS COMMON BUT NOTABLE SIDE EFFECTS:
• Hypoglycaemia: low risk with Rybelsus alone; SIGNIFICANT RISK if combined with sulfonylureas or insulin — monitor blood glucose closely
• Fatigue and dizziness (particularly early in treatment)
• Increased heart rate (mild)
• Diabetic retinopathy worsening: rapid HbA1c improvement has been associated with transient worsening in patients with pre-existing retinopathy
SERIOUS SIDE EFFECTS (contact your doctor immediately):
• Acute Pancreatitis: severe, persistent abdominal pain radiating to the back — STOP RYBELSUS and seek emergency care
• Diabetic Retinopathy Complications: sudden vision changes, floaters, or loss of vision — urgent ophthalmology review
• Severe allergic reactions / anaphylaxis: facial swelling, hives, difficulty breathing
• Acute kidney injury: significant dehydration secondary to GI adverse effects can impair renal function
EMERGENCY SIGNS — SEEK IMMEDIATE MEDICAL HELP:
• Severe, persistent abdominal pain radiating to the back (possible pancreatitis)
• Sudden vision changes or loss
• Throat tightening, facial swelling, or difficulty breathing (anaphylaxis)
• Severe persistent vomiting with inability to retain fluids (dehydration / renal risk)
How to use:
DOSE ESCALATION PROTOCOL (mandatory for GI tolerability):
• Start: Rybelsus 3mg once daily for 30 days (initiation/tolerability dose — NOT therapeutic)
• Escalate to: Rybelsus 7mg once daily for at least 30 days
• Escalate to: Rybelsus 14mg once daily (therapeutic maintenance dose — maximum dose)
• Note: Rybelsus 14mg is the maximum approved dose. Do NOT exceed 14mg/day.
CRITICAL ADMINISTRATION RULES (non-negotiable for adequate absorption):
• Take on an EMPTY STOMACH — at least 30 minutes before first food, drink (other than plain water), or any other oral medicine
• Swallow WHOLE with no more than 120ml (half a glass) of PLAIN WATER ONLY
• Do NOT crush, chew, split, or dissolve the tablet
• Do NOT take with coffee, juice, milk, mineral water, or other beverages
• If you miss the 30-minute window: skip that day's dose — do NOT take later in the day
COMBINATION USE:
• With metformin: no dose adjustment required
• With sulfonylureas or insulin: consider dose reduction of the sulfonylurea/insulin to reduce hypoglycaemia risk
• With SGLT2 inhibitors: generally well tolerated; monitor renal function
MISSED DOSE:
• If missed on a given day: skip and take next dose the following morning as usual
• Do NOT double-dose
RENAL IMPAIRMENT:
• No dose adjustment required; however, GI side effects may be more pronounced
HEPATIC IMPAIRMENT:
• No dose adjustment required for mild-moderate impairment
STORAGE:
• Store below 30°C in original packaging, away from heat and moisture
• Do NOT refrigerate or freeze
• Keep out of reach of children
• Discard after expiry date printed on the strip
How it works:
In type 2 diabetes, GLP-1 secretion after meals is impaired, contributing to hyperglycaemia.
Semaglutide binds to GLP-1 receptors throughout the body, triggering multiple glucose-lowering mechanisms:
• GLUCOSE-DEPENDENT INSULIN STIMULATION: Stimulates pancreatic beta cells to release insulin only when blood glucose is elevated — markedly reducing hypoglycaemia risk compared to sulfonylureas
• GLUCAGON SUPPRESSION: Suppresses pancreatic alpha cell glucagon secretion post-meal, reducing hepatic glucose output
• GASTRIC EMPTYING DELAY: Slows gastric motility, blunting post-meal glucose excursions
• APPETITE & SATIETY REGULATION: Acts on hypothalamic GLP-1 receptors to reduce appetite and increase satiety, driving weight loss
KEY CLINICAL ADVANTAGES:
• World's first and only oral GLP-1 receptor agonist — no injections required
• Half-life ~1 week — once-daily dosing despite oral absorption
• Proven HbA1c reduction of up to 1.4% (PIONEER trials)
• Average body weight reduction 3–4 kg vs placebo
• Low intrinsic hypoglycaemia risk (glucose-dependent mechanism)
• Cardiovascular and renal protective signals consistent with GLP-1 drug class
Faq for medicine:
Rybelsus 14mg (Semaglutide) is a once-daily oral GLP-1 receptor agonist used to manage type 2 diabetes in adults. It improves blood sugar control, reduces HbA1c by up to 1.4%, and promotes clinically meaningful weight loss as an adjunct to diet and exercise.
2. How does Rybelsus 14mg Semaglutide Tablet work?
Semaglutide mimics GLP-1, stimulating glucose-dependent insulin release, suppressing post-meal glucagon, slowing gastric emptying, and reducing appetite. Its SNAC formulation enables oral absorption through the gastric mucosa — a world-first for GLP-1 receptor agonist therapy.
3. How should I take Rybelsus 14mg Tablet?
Take Rybelsus 14mg on an empty stomach each morning with up to 120ml of plain water only. Wait at least 30 minutes before eating, drinking (anything other than water), or taking other oral medicines. Never crush or chew the tablet. Always follow your diabetologist's prescription.
4. What are the side effects of Rybelsus 14mg Semaglutide Tablet?
Most common: nausea, vomiting, diarrhoea, decreased appetite — typically during dose escalation, resolving within weeks. Serious but rare: acute pancreatitis (severe abdominal pain), diabetic retinopathy worsening, severe allergic reactions. Report persistent abdominal pain immediately.
5. Can I buy Rybelsus 14mg Tablets online at the best price in India?
Yes. Buy Rybelsus 14mg Tablets online from Shabbir Medical Hall at 10% OFF MRP (Rs 3,265.32 vs Rs 3,628.13 per strip of 10 tablets). Valid diabetologist prescription required. Fast delivery across Hyderabad, Bangalore, Mumbai, Delhi, and Chennai.
Medicine interaction:
• Sulfonylureas (glibenclamide, glipizide, gliclazide): significantly increased hypoglycaemia risk; reduce sulfonylurea dose when initiating Rybelsus
• Insulin (all types): increased hypoglycaemia risk; insulin dose reduction may be required
• Warfarin / oral anticoagulants: Semaglutide may alter INR; more frequent INR monitoring required on initiation or dose change
• Oral medications with narrow therapeutic windows (levothyroxine, digoxin, cyclosporin): Rybelsus delays gastric emptying — take these at least 30 minutes AFTER Rybelsus to minimise absorption variability
• Oral contraceptives: delayed gastric emptying may affect absorption timing; consider taking OCP well after Rybelsus
• Other GLP-1 receptor agonists (injectable): do NOT combine — additive risk of GI adverse effects and pancreatitis
• DPP-4 inhibitors (sitagliptin, vildagliptin): generally avoid combination — overlapping GLP-1 pathway, limited added benefit, increased GI risk
VACCINE INTERACTIONS:
• No known clinically significant interactions with vaccines
SUPPLEMENT INTERACTIONS:
• Chromium picolinate, bitter melon, or other blood-sugar-lowering supplements: monitor glucose closely — additive hypoglycaemic effect possible
• Always inform your physician and pharmacist of all herbal products, vitamins, and supplements
